LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019. The event will highlight CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Company intends to advance CTP-692 into Phase 2 clinical evaluation in the fourth quarter of 2019.
The webcast event will feature a discussion by Joseph T. Coyle, MD of McLean Hospital and Harvard Medical School, who will discuss the N-methyl-d-aspartate (NMDA) mechanism and potential utility of CTP-692 in treating schizophrenia. Concert’s management team will also provide an update on the development activities relating to CTP-692.
The Company will host a conference call and webcast on November 14, 2019, 8:30 – 9:30 a.m. ET. To access the conference call, please dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International) five minutes prior to the start time. A live and archived webcast of the event, with slides, may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.
Joseph T. Coyle, MD
Dr. Coyle currently serves as Director, Laboratory for Psychiatric and Molecular Neuroscience at McLean Hospital. He is also the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard Medical School (1991-present) and was chairman of the Consolidated Department of Psychiatry at Harvard (1991-2001). A graduate of the College of the Holy Cross, he received his MD from Johns Hopkins. He completed an internship in pediatrics, a residency in psychiatry, and a fellowship with the Nobel laureate Julius Axelrod, PhD. He joined the Hopkins faculty in 1975 and was named the Distinguished Service Professor of Child Psychiatry in 1985.
Dr. Coyle is a member of the National Academy of Medicine (1990), a fellow of the American Academy of Arts and Sciences (1993), and a distinguished fellow of the American Psychiatric Association. He is past president of the American College of Neuropsychopharmacology (2001) and of the Society for Neuroscience (1991). He was editor of JAMA Psychiatry.
About CTP-692 and Schizophrenia
CTP-692 is an investigational deuterium-modified form of d‑serine that offers an entirely new mechanism of action to treat schizophrenia, potentially more broadly addressing its symptoms than has been previously possible. The underlying basis of the current antipsychotic therapies for schizophrenia is that excessive dopaminergic neurotransmission and dysfunctional D2 receptor signaling play key pathophysiological roles in the disease, and consequently all typical and atypical antipsychotics in clinical practice possess some level of D2 antagonist activity. In contrast, it has been reported that individuals with schizophrenia have low levels of D-serine, a key molecule that activates NMDA receptors in areas of the brain that are widely believed to play key roles in schizophrenia. CTP-692 administration may help address this d‑serine deficiency. CTP-692 is being initially developed as an adjunctive therapy with the potential to improve positive and negative symptoms as well as cognitive function in patients with schizophrenia.
Schizophrenia is a chronic and devastating neuropsychiatric disorder that is ranked as a leading cause of disability worldwide. The disease afflicts nearly 1% of the world’s population, affecting both men and women, and striking all ethnic and socioeconomic groups with a similar level of prevalence. The illness is characterized by multiple symptoms that are categorized into three main clusters known as positive symptoms (hallucinations, delusional behaviors and thought disorder), negative symptoms (social withdrawal, flattened affect and poverty of speech), and cognitive dysfunction (diminished capacity for attention, working memory and executive function). Currently available antipsychotic drugs offer some benefit for positive symptoms but are frequently associated with neurologic and metabolic adverse effects. Many patients are not adequately treated since currently available treatments are limited in their capacity to treat negative symptoms and cognitive dysfunction which are related to poor functional outcomes.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including, among others, statements about the progress of clinical development of CTP-692, and any other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.
Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
Kathryn Morris (media)
The Yates Network